Fig. 4
Early dopaminergic dysfunction in AAV-hTyr-injected rats. a Contralateral forepaw use in AAV-hTyr- and AAV-EV-injected rats, as assessed with the cylinder test. *p ≤ 0.05, compared to AAV-EV-injected animals at the same time-point; #p < 0.05, compared to 0.5 m AAV-hTyr animals (two-way ANOVA; Student–Newman–Keuls post-hoc test). b Striatal DA release in AAV-hTyr- and vehicle-injected rats measured by microdialysis in the ipsilateral striatum following local amphetamine (left) or veratridine (right) administration by reverse-dialysis. *p < 0.05, compared to vehicle-injected animals (ANOVA for repeated measures of the DA values during the specified time periods; Tukey’s post-hoc test). Baseline DA concentration (fmol/fraction-20 min): amphetamine experiments, 82.83 ± 19.16 (vehicle) vs 94.38 ± 21.82 (AAV-hTyr); veratridine experiments, 25.52 ± 4.33 (vehicle) vs 29.93 ± 6.46 (AAV-hTyr). c Striatal DA release in AAV-hTyr- and vehicle-injected rats measured by microdialysis in the ipsilateral striatum following electrical stimulation of the MFB for 10-min periods under S1 and S2 conditions (S1, 2.0 Hz, 0.1 mA, 0.2 ms; S2, 10 Hz, 0.1 mA, 1 ms). *p < 0.05, compared to stimulated AAV-hTyr-injected rats (ANOVA for repeated measures; Tukey’s post-hoc test). Baseline DA concentration (fmol/fraction-10 min): 16.8 ± 2.38 (vehicle) vs 23.02 ± 6.37 (AAV-hTyr). In all panels, values are mean ± SEM. In a, AAV-EV-injected rats n = 20 (0.5 m), n = 20 (1 m), n = 9 (2 m), n = 9 (3 m), n = 8 (6 m), n = 12 (12 m), n = 4 (24 m); and AAV-hTyr-injected rats n = 29 (0.5 m), n = 8 (1 m), n = 21 (2 m), n = 14 (3 m), n = 7 (6 m), n = 14 (12 m), n = 6 (24 m). In b, c, experiments were performed at 1-2 m post-AAV injection. In b, n = 6 vehicle-injected, n = 6 AAV-hTyr-injected rats + Amphetamine and n = 8 AAV-hTyr-injected rats + Veratridine. In c, n = 4 animals per group
